Confluence Pharmaceuticals
PrivateLast Round
Debt
Jun 21, 2022
Total Funding Raised
$2.1M
Company Overview
Confluence Pharmaceuticals is a biotechnology company developing novel therapeutic treatments for social and communication impairments caused by Fragile X Syndrome and Autism Spectrum Disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Confluence Pharmaceuticals Comparables
Compare Confluence Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Yamo Pharmaceuticals | 86% | |
| Kaerus Bioscience | 84% | |
| PaxMedica, Inc. | 83% |
Confluence Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Jun 21, 2022 | ||||
| VC Round | Jun 17, 2021 | ||||
| Debt | Dec 2, 2020 | ||||
| VC Round | Dec 20, 2018 | ||||
| Series A Extension | Sep 20, 2016 |
Confluence Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Elevate Ventures | Series A Extension |
| IU Ventures | Debt, VC Round |
| IU Philanthropic Venture Fund | Debt, VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 2, 2020
$100K round from IU Philanthropic Venture Fund.
- Sep 20, 2016
$1.3M round with Elevate Ventures and 21st-century-research-and-technology-fund.
Confluence Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Confluence Pharmaceuticals's valuation, stock price, and market status.
Is Confluence Pharmaceuticals a public or private company?
Confluence Pharmaceuticals is a private company.
What is the current stock price of Confluence Pharmaceuticals?
Confluence Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Confluence Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Confluence Pharmaceuticals worth (valuation)?
Valuation information for Confluence Pharmaceuticals is not publicly available.
Can I buy Confluence Pharmaceuticals stock?
Confluence Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Confluence Pharmaceuticals's last funding round?
Confluence Pharmaceuticals's most recent funding round was Debt on June 21, 2022.
Who are the main investors in Confluence Pharmaceuticals?
Key investors in Confluence Pharmaceuticals include Elevate Ventures, IU Ventures, IU Philanthropic Venture Fund.
Will Confluence Pharmaceuticals IPO soon?
No public IPO plans have been announced for Confluence Pharmaceuticals.
How can I track Confluence Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Confluence Pharmaceuticals's shares on secondary markets.